Article and Video CATEGORIES

Cancer Journey

Search By

Targeted Therapies in Lung Cancer Patient Forum 2017 - Presentations and Handouts
Author
GRACE Videos and Articles

Videos from the webcast Targeted Therapies Patient Forum 2017 are available for viewing, and for those who prefer to read the material, GRACE has made all speaker presentations and handouts available.  We have also included links to helpful social media and patient groups.  

Again, huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event - Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.  

We started the day out with a warm welcome from our Forum Chair - Dr. Nathan Pennell.  For the full agenda, faculty list, presentations, and videos from the webcast, please visit the 'webcast details' page, available via this link.  For those who would like to view the presentations from the Targeted Therapies Patient Forum in Cleveland, please view and download all presentations and handouts here, or continue on for a list of what is available.   

 

The morning sessions kicked off with a warm welcome from Dr. Pennell.  

 
The Many Faces of Progression
Dr. Nathan Pennell, Cleveland Clinic Cancer Center  
 
The Role of Local Therapy
Dr. Shirish Gadgeel, Michigan Medicine, University of Michigan  
 
Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope Comprehensive Cancer Center 
 
The Question of Clinical Trials
Dr. Alice Shaw, Massachusetts General Hospital
 
The Crossroads:
Local Therapy, Chemo, Targeted  Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell,  Gadgeel, Reckamp, and Shaw, and patients John Cherol (EGFR), Matt  Hiznay (ALK), and Sara Whitlock (RET), Moderator: Dr. H. (Jack) West
 
After lunch the breakout discussions continued: 
 
Dr. Alice Shaw, Dr. Shirish Gadgeel, and Matt Hiznay, ALK patient
 
ALK-positive NSCLC: ALK Positive
“ALK Positive” on Facebook (closed group): https://www.facebook.com/groups/ALKPositive/ 
“ALK Positive Outreach” on Facebook (public group): https://www.facebook.com/groups/ALKPositiveOR/
 
ROS1-positive cancer (any cancer):  The ROS1ders
“ROS1 Positive (ROS1+) Cancer” on Facebook (private group):  https://www.facebook.com/groups/ROS1cancer/
“ROS1 Cancer Research Forum” on Facebook (public community): https://www.facebook.com/ROS1CancerResearchForum/
“The ROS1ders” website: http://ros1cancer.com
 
Dr. Nathan Pennell, Dr. H. (Jack) West, and John Cherol, EGFR patient
 
EGFR-positive NSCLC
“LUNGevity EGFR Group” on Facebook (closed group): https://www.facebook.com/groups/EGFRlung/
EGFR-positive patients who have developed resistance to at least one TKI
EGFR Resisters Lung Cancer Patient Group” on Facebook: https://www.facebook.com/groups/1992981107603006/
EGFR-positive Exon 20 insertion cancer (any cancer)
“Exon20 Group” website http://www.exon20group.org/
 
Dr. Karen Reckamp, Dr. Vamsidhar  Velcheti, and Sara Whitlock, RET patient 
 
The day concluded with the afternoon general session: 
 
 
Managing the Cost of Cancer Care
Dr. James P. Stevenson, Cleveland Clinic Cancer Center
 
Patient to Patient Mentoring
Kathryn Sefcek, MHA, 4th Angel Mentoring Program  
 
Caveat Emptor: Assessing Cancer Information from Sources of  Varying Quality  
Dr. H. (Jack) West, Swedish Cancer Institute & Founder of  cancerGRACE, and Janet Freeman-Daily, ROS1 patient,  #LCSM Twitter Chat co- moderator, Cure  Today contributor, blogger.

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on